- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 09.06. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 934 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 299 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 202 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen | |
| 23.09.25 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 339 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial | ||
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,330 | -0,30 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,958 | -2,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 20,870 | +0,72 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,310 | +1,55 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,310 | -0,03 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| COHERUS ONCOLOGY | 1,215 | 0,00 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| CURIS | 1,462 | +14,43 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,074 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,875 | +3,27 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen |
Das Unternehmen CYCLERION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,79 % bei einem Aktienkurs von 3,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.